Age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of severe loss of central vision in older adults. It destroys central vision and leaves peripheral vision alone. This lesson explains drusen, geographic atrophy and choroidal neovascularisation, how each shows on OCT and angiography, and how NICE NG82 wants suspected wet AMD referred and treated.
The tissue that fails
The photoreceptors do not look after themselves. Behind them lies the retinal pigment epithelium (RPE), a single layer of cells that recycles visual pigment, digests the tips of the photoreceptor outer segments shed every day, and pumps fluid out of the subretinal space. The RPE sits on Bruch's membrane, a thin sheet of collagen and elastin, and behind that is the choriocapillaris, which supplies oxygen to the outer retina.
3D atlasAMD is a disease of the photoreceptor, RPE, Bruch's membrane and choriocapillaris complex at the macula.With age, waste that the RPE cannot clear builds up between the RPE and Bruch's membrane as yellow deposits called drusen. They are rich in lipid, protein and inflammatory components, including complement. Drusen are the hallmark of AMD. Bruch's membrane thickens, exchange between choroid and RPE worsens, and the RPE and photoreceptors over the deposits begin to fail.
Risk factors, as listed by NICE, are older age, AMD in the other eye, family history, smoking, hypertension, a body mass index of 30 or more, a diet low in omega-3 and antioxidant vitamins or high in fat, and lack of exercise. Smoking is the strongest modifiable one. Much of the inherited risk is carried by variants in complement factor H, an inhibitor of the alternative complement pathway, which is why complement inhibitors have been developed as treatments.
Early and late disease
Drusen are graded by size. Small 'hard' drusen (under 63 micrometres) are a normal ageing change. Medium drusen (63 to 124 micrometres) and large, soft drusen (125 micrometres or more) define early AMD, and the risk of progression rises with drusen size and with pigment clumping at the RPE. Early AMD usually causes no symptoms.
Late AMD takes two forms. NICE NG82 uses the terms late AMD (dry) and late AMD (wet active), and asks clinicians not to call a scarred, burnt-out wet lesion 'dry'.
| Late dry AMD | Wet (neovascular) AMD | |
|---|---|---|
| Lesion | Geographic atrophy: sharply edged patches where RPE, photoreceptors and choriocapillaris have died | Choroidal neovascularisation: new vessels from the choroid growing through Bruch's membrane |
| Share of AMD | With early disease, about 85 to 90% of all AMD | About 10 to 15%, but most of the severe visual loss |
| Onset | Gradual, over years | Days to weeks |
| Main symptom | Slowly enlarging central blur or gaps in words | Distortion (metamorphopsia), then a central dark patch |
| Fundus | Pale patches with visible large choroidal vessels, drusen | Grey-green subretinal lesion, haemorrhage, exudate, fluid |
| OCT | Loss of outer retinal layers and RPE, no fluid | Subretinal or intraretinal fluid, pigment epithelial detachment |
| Treatment | Support and low-vision aids | Intravitreal anti-VEGF |
In geographic atrophy the patches often start beside the fovea and spare it until late, so a patient may read single letters on a chart well but lose their place in a line of text. In choroidal neovascularisation (CNV), VEGF from stressed RPE draws new vessels out of the choriocapillaris. They may stay under the RPE (type 1, 'occult' on angiography), break through into the subretinal space (type 2, 'classic'), or arise within the retina itself (type 3, retinal angiomatous proliferation). The vessels leak fluid and bleed, lifting and distorting the photoreceptor layer, and if untreated they heal as a fibrous disciform scar with permanent loss of central vision.
Symptoms and the Amsler grid
Wet AMD announces itself with metamorphopsia: straight lines such as door frames look bent, because fluid has shifted the photoreceptors out of their regular array. Objects may look smaller (micropsia) when the photoreceptors are spread apart. A grey or dark central patch (scotoma) follows. Peripheral vision is preserved, so patients do not go completely blind and can usually still move around unaided.
The Amsler grid is a 10 cm square of regular lines with a central dot. The patient wears reading glasses, covers one eye, holds the chart at reading distance, about 30 cm (sources quote 28 to 33 cm), and looks at the dot. The grid then tests roughly the central 20 degrees of field, 10 degrees either side of fixation. Wavy or missing lines suggest macular disease. Its sensitivity is low, so a normal grid does not exclude wet AMD. NICE asks people with AMD to report any new distortion, grey patch or apparent shrinking of objects promptly.
Investigation and referral
Early AMD and late dry AMD are diagnosed by slit-lamp examination of the fundus. NICE says people with asymptomatic early AMD should not be referred to hospital, and neither early nor late dry AMD should be monitored routinely in hospital eye services.
Suspected wet AMD is different. NICE says to make an urgent referral to a macula service, normally within 1 working day, whether or not acuity is reduced. The service performs optical coherence tomography (OCT), a cross-sectional scan that shows fluid under or within the retina and elevation of the RPE (pigment epithelial detachment). If examination and OCT exclude neovascularisation, no angiogram is needed. If they do not, fundus fluorescein angiography confirms it. Classic CNV shows a well-defined lacy network that fills early and leaks. Occult CNV shows ill-defined late leakage. Treatment should begin within 14 days of referral.
Anti-VEGF treatment
Wet AMD is treated with drugs that block VEGF, injected through the pars plana into the vitreous under topical anaesthetic. Blocking VEGF stops the leak and halts growth of the membrane. It does not remove the vessels, so treatment continues for years.
| Drug | What it is | Notes |
|---|---|---|
| Ranibizumab | Antibody fragment against VEGF-A | NICE-recommended |
| Aflibercept | Fusion protein of VEGF receptor domains that binds VEGF-A, VEGF-B and placental growth factor | NICE-recommended. Licensed schedule for the 2 mg dose: three monthly injections, then one every 2 months |
| Faricimab | Bispecific antibody against VEGF-A and angiopoietin-2 | NICE-recommended (TA800). Many patients manage intervals of 3 months or longer |
| Bevacizumab | Full antibody against VEGF-A, made for cancer treatment | The cancer infusion is not licensed for the eye and was long used off-label. NG82 found no clinically significant difference in effectiveness or safety from ranibizumab and aflibercept. An ophthalmic formulation, bevacizumab gamma, is now licensed and NICE-recommended (TA1022, 2024). The two are not interchangeable |
NICE technology appraisals fund ranibizumab, aflibercept, faricimab and bevacizumab gamma (and also brolucizumab) when acuity is between 6/12 and 6/96, there is no permanent structural damage to the central fovea, the lesion is no larger than 12 disc areas and there is evidence of recent progression. NG82 adds that treatment at acuity better than 6/12 is clinically effective, and that eyes at 6/96 or worse should be treated only if overall visual function is expected to benefit.
All regimens begin with a loading phase of monthly injections. After that there are three ways to continue: fixed-interval dosing, 'as needed' dosing with monthly OCT review, or treat and extend, in which an injection is given at every visit and the gap to the next visit is lengthened while the macula stays dry and shortened if fluid returns. The main serious risk of any intravitreal injection is endophthalmitis (infection inside the eye).
Slowing the disease and living with it
Stopping smoking is the most useful advice at any stage. The AREDS trials tested high-dose antioxidant supplements. In people with intermediate AMD, or late AMD in one eye, the formula reduced progression to late AMD by about 25%. It does not prevent AMD starting and does not help early disease. The original formula contained vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg, zinc 80 mg and copper 2 mg. AREDS2 replaced beta-carotene with lutein 10 mg and zeaxanthin 2 mg, because beta-carotene raised the incidence of lung cancer in former smokers. Current and former smokers should use the AREDS2 formula. The NG82 recommendations do not include a supplement, so in the UK patients buy these themselves.
For geographic atrophy, two intravitreal complement inhibitors, pegcetacoplan (against C3) and avacincaptad pegol (against C5), slowed the growth of atrophy in trials and were approved in the United States in 2023. They do not restore vision, and pegcetacoplan increased the rate of new wet AMD. They are not part of NG82, and their place in UK practice is not settled.
Support matters as much as injections. NICE asks clinicians to offer certification as sight impaired or severely sight impaired as soon as a person is eligible, even during active treatment, to consider referral to low-vision services, to discuss driving standards, and to remember that depression is more common in people with AMD.
Summary
- AMD is degeneration of the photoreceptor, RPE, Bruch's membrane and choriocapillaris complex at the macula; drusen are its hallmark.
- Drusen lie between the RPE and Bruch's membrane; larger drusen and pigment change mean higher risk of progression.
- Late dry AMD is geographic atrophy and progresses over years; wet AMD is choroidal neovascularisation and progresses over days to weeks.
- Metamorphopsia is the key symptom of wet AMD and can be detected on an Amsler grid held at reading distance.
- NICE NG82: refer suspected wet AMD to a macula service within 1 working day and treat within 14 days.
- OCT is the first investigation; fluorescein angiography is used only if OCT cannot exclude neovascularisation.
- Wet AMD is treated with intravitreal anti-VEGF (ranibizumab, aflibercept, faricimab), funded by NICE for acuity between 6/12 and 6/96.
- Treat and extend lengthens the interval between injections while the macula stays dry.
- AREDS2 supplements reduce progression from intermediate to late AMD by about 25% and contain no beta-carotene.
- Smoking is the main modifiable risk factor.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.